glp 1 and estrogen Semaglutide Menopause: Does It Work? The Impact of GLP1 Agonists

#GenericDrugsMarket #GenericPharmaceuticals #AffordableHealthcare #PharmaIndustry #HealthcareMarket #DrugManufacturing #Biosimilars #APIManufacturing #PharmaGrowth #HealthcareAccess #PrescriptionDrugs #PharmaTrends #GlobalHealthcare #CostEffectiveMedicine #RegulatoryCompliance #BrandedGenerics #PharmaceuticalInnovation #MarketResearch #HealthcareEconomy To view or add a comment, sign in 4,792 followers

Patients who received SC semaglutide once a week for 68 weeks continued to lose an average of 18.2%

Dropout rates reach 40 to 50 percent in some cohorts, a rate comparable to GLP-1 discontinuation rates that approach 50 percent within two years

Additionally, stopping Ozempic without medical supervision means missing the opportunity to implement alternative treatments or lifestyle modifications that could maintain the benefits achieved during treatment

Dulaglutide should not be used in pregnant or breastfeeding women